Hussman Strategic Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Hussman Strategic Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.74M	Buy	168,000 +21,000	+14%	+$502K	0.81%	12
2025 Q4	$3.93M	Buy	147,000 +21,000	+17%	+$502K	0.95%	7
2025 Q3	$2.69M	Buy	+126,000	New	+$2.98M	0.58%	50
2024 Q3	–	Sell	-42,000	Closed	-$683K	–	220
2024 Q2	$683K	Hold	42,000	–	–	0.19%	172
2024 Q1	$777K	Hold	42,000	–	–	0.18%	158
2023 Q4	$1.32M	Hold	42,000	–	–	0.3%	134
2023 Q3	$875K	Sell	42,000 -20,000	-32%	-$543K	0.17%	213
2023 Q2	$1.48M	Sell	62,000 -31,000	-33%	-$689K	0.27%	168
2023 Q1	$1.75M	Buy	+93,000	New	+$1.77M	0.27%	151

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Hussman Strategic Advisors's ACAD Position: Q1 2026 in Review

Hussman Strategic Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 14% in Q1 2026, buying an estimated $502K and bringing the position to 168,000 shares worth $3.74M. The position accounts for 0.81% of the portfolio, ranked #12.

Hussman Strategic Advisors first reported a position in ACAD in Q1 2023 and has held it in 9 quarters since. The position peaked at $3.93M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Hussman Strategic Advisors held 168,000 shares of Acadia Pharmaceuticals worth $3.74M as of Q1 2026.
Hussman Strategic Advisors bought 21,000 Acadia Pharmaceuticals shares in Q1 2026, an estimated $502K.
Acadia Pharmaceuticals made up 0.81% of Hussman Strategic Advisors's portfolio in Q1 2026, its #12 holding.
Hussman Strategic Advisors first reported a position in Acadia Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
Hussman Strategic Advisors's Acadia Pharmaceuticals position peaked at $3.93M in Q4 2025.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.